Multiple Chinese biotechs appear to have renewed enthusiasm for the application of artificial intelligence (AI) to help discover and develop novel therapeutics and vaccines following the December breakout release of DeepSeek-R1, a homegrown open-source generative AI application that has taken the world by storm.
Key Takeaways
- Chinese biotech Harbour BioMed and AI-assisted US firm InSilico Medicine have teamed up for the discovery of novel antibodies, in one sign of Chinese companies' renewed interest in AI tools.
While the AI-driven discovery of small molecules has been developing for years, Chinese biotech Harbour BioMed and InSilico Medicine, a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?